Aprea Therapeutics (NASDAQ:APRE) Shares Up 2.8% – Here’s What Happened

Aprea Therapeutics, Inc. (NASDAQ:APRE)’s stock price shot up 2.8% on Friday . The stock traded as high as $1.70 and last traded at $1.65. 41,193 shares traded hands during trading, a decline of 20% from the average session volume of 51,390 shares. The stock had previously closed at $1.60.

Analyst Ratings Changes

Separately, Wedbush reissued an “outperform” rating and set a $11.00 target price on shares of Aprea Therapeutics in a research report on Thursday, June 26th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Aprea Therapeutics currently has an average rating of “Buy” and an average target price of $15.50.

Aprea Therapeutics Trading Up 2.8%

The firm’s fifty day moving average price is $1.73 and its 200 day moving average price is $1.97. The firm has a market capitalization of $9.59 million, a PE ratio of -0.71 and a beta of 1.29.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.24. The business had revenue of $0.12 million for the quarter. Aprea Therapeutics had a negative net margin of 1,645.01% and a negative return on equity of 78.90%. On average, analysts predict that Aprea Therapeutics, Inc. will post -2.55 earnings per share for the current year.

Hedge Funds Weigh In On Aprea Therapeutics

Several large investors have recently made changes to their positions in APRE. LPL Financial LLC acquired a new position in shares of Aprea Therapeutics in the 4th quarter valued at $53,000. BNP Paribas Financial Markets acquired a new position in Aprea Therapeutics during the fourth quarter worth $43,000. Finally, Stonepine Capital Management LLC raised its position in Aprea Therapeutics by 8.8% during the fourth quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock worth $491,000 after acquiring an additional 12,047 shares during the period. 34.19% of the stock is currently owned by institutional investors and hedge funds.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.